Insmed received FDA approval for Brinsupri (brensocatib), the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease affecting approximately 500,000 U.S. patients. Brensocatib is a dipeptidyl peptidase 1 inhibitor that targets neutrophilic inflammation, addressing a root cause of disease exacerbations. The drug demonstrated efficacy in Phase 3 trials by reducing pulmonary exacerbations and is positioned to become a major growth driver for Insmed.